RxDoctor Payments Data

Carie Bodnar

Acute Care · Tyler, TXNPI 1568071116

Payments from drug & device makers

$4,798in general payments, 2019–2025

Across 113 payments — averaging $42.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Janssen Scientific Affairs, LLC$952
  • Sanofi$558
  • Madrigal Pharmaceuticals$339
  • Gilead$253
  • Johnson & Johnson$179
  • plus $793 from 11 others

What the payments were for

  • Food & beverage$4,70998%
  • Education$892%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,798 in reported general payments places this provider in the 90th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas

Medicare billing

Part B allowed, 2024
$33,377
Medicare patients
303
Services billed
451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin11$28,174
LinzessLinaclotide21$13,593
Pantoprazole Sodium186$1,951
Lubiprostone24$1,776
Colestipol Hcl26$1,217
Omeprazole59$932
Dicyclomine Hcl39$912
Ondansetron OdtOndansetron37$895
Famotidine67$613
Esomeprazole Magnesium12$350
Spironolactone15$281
Mirtazapine27$169
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine14$150
Furosemide13$44

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,725$13,59321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,323 acute care providers in Texas.

Other acute care in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →